Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explorer7: concizumab prophylaxis in haemophilia A or B with inhibitors
jRCT2080224957Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of concizumab in hemophilia A and hemophilia B (HB) (4 arms), sponsored by Novo Nordisk. Started Nov 2019; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2080224957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224957.